206 related articles for article (PubMed ID: 30992266)
1. Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation.
Baker KS; Leisenring WM; Goodman PJ; Ermoian RP; Flowers ME; Schoch G; Storb R; Sandmaier BM; Deeg HJ
Blood; 2019 Jun; 133(26):2790-2799. PubMed ID: 30992266
[TBL] [Abstract][Full Text] [Related]
2. Risk of Subsequent Malignant Neoplasms Following Hematopoietic Stem Cell Transplantation with Total Body Irradiation or Total Marrow Irradiation: Insights from Early Follow-Up.
Ladbury C; Armenian S; Bosworth A; He T; Wong FL; Dandapani S; Han C; Liu A; Al Malki M; Rosenthal J; Stein A; Wong J
Transplant Cell Ther; 2022 Dec; 28(12):860.e1-860.e6. PubMed ID: 36167306
[TBL] [Abstract][Full Text] [Related]
3. Second malignancies after autologous hematopoietic cell transplantation in children.
Danner-Koptik KE; Majhail NS; Brazauskas R; Wang Z; Buchbinder D; Cahn JY; Dilley KJ; Frangoul HA; Gross TG; Hale GA; Hayashi RJ; Hijiya N; Kamble RT; Lazarus HM; Marks DI; Reddy V; Savani BN; Warwick AB; Wingard JR; Wood WA; Sorror ML; Jacobsohn DA
Bone Marrow Transplant; 2013 Mar; 48(3):363-8. PubMed ID: 22964594
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation.
Nunez L; Abedin T; Naqvi S; Shen H; Chaudhry A; Bellerby S; Savoie L; Daly A; Shafey M; Duggan P; Storek J; Jamani K
Blood Adv; 2022 Feb; 6(3):767-773. PubMed ID: 34995342
[TBL] [Abstract][Full Text] [Related]
6. Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report.
McDonald AM; Chen Y; Wu J; Hageman L; Francisco L; Kung M; Wong FL; Ness E; Landier W; Battles K; Salzman D; Weisdorf DJ; Forman SJ; Arora M; Armenian SH; Bhatia S
J Clin Oncol; 2020 Sep; 38(25):2872-2882. PubMed ID: 32673169
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Risk Factors in Survivors of Childhood Hematopoietic Cell Transplantation Treated with Total Body Irradiation: A Longitudinal Analysis.
Friedman DN; Hilden P; Moskowitz CS; Suzuki M; Boulad F; Kernan NA; Wolden SL; Oeffinger KC; Sklar CA
Biol Blood Marrow Transplant; 2017 Mar; 23(3):475-482. PubMed ID: 28040534
[TBL] [Abstract][Full Text] [Related]
8. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose.
Constine LS; Tarbell N; Hudson MM; Schwartz C; Fisher SG; Muhs AG; Basu SK; Kun LE; Ng A; Mauch P; Sandhu A; Culakova E; Lyman G; Mendenhall N
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):24-33. PubMed ID: 18722263
[TBL] [Abstract][Full Text] [Related]
9. Influence of Total Body Irradiation Dose Rate on Idiopathic Pneumonia Syndrome in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
Gao RW; Weisdorf DJ; DeFor TE; Ehler E; Dusenbery KE
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):180-189. PubMed ID: 30205123
[TBL] [Abstract][Full Text] [Related]
10. Factors Influencing Pulmonary Toxicity in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in the Setting of Total Body Irradiation-Based Myeloablative Conditioning.
Abugideiri M; Nanda RH; Butker C; Zhang C; Kim S; Chiang KY; Butker E; Khan MK; Haight AE; Chen Z; Esiashvili N
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):349-59. PubMed ID: 26853343
[TBL] [Abstract][Full Text] [Related]
11. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
12. Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms.
Monaco F; Scott BL; Chauncey TR; Petersen FB; Storer BE; Baron F; Flowers ME; Deeg HJ; Maloney DG; Storb R; Sandmaier BM
Haematologica; 2019 Jun; 104(6):1221-1229. PubMed ID: 30630975
[TBL] [Abstract][Full Text] [Related]
13. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
14. Risk of Subsequent Neoplasms During the Fifth and Sixth Decades of Life in the Childhood Cancer Survivor Study Cohort.
Turcotte LM; Whitton JA; Friedman DL; Hammond S; Armstrong GT; Leisenring W; Robison LL; Neglia JP
J Clin Oncol; 2015 Nov; 33(31):3568-75. PubMed ID: 26261260
[TBL] [Abstract][Full Text] [Related]
15. Subsequent malignant neoplasms after primary hematological malignancy in adult patients.
Rönkkö RM; Nevala AO; Pitkäniemi JM; Wartiovaara-Kautto UM; Malila NK
Int J Cancer; 2024 Apr; ():. PubMed ID: 38664865
[TBL] [Abstract][Full Text] [Related]
16. Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation.
Schwartz JL; Kopecky KJ; Mathes RW; Leisenring WM; Friedman DL; Deeg HJ
Radiat Res; 2009 Feb; 171(2):155-63. PubMed ID: 19267540
[TBL] [Abstract][Full Text] [Related]
17. The importance of age, fludarabine, and total body irradiation in the incidence and severity of chronic renal failure after allogeneic hematopoietic cell transplantation.
Delgado J; Cooper N; Thomson K; Duarte R; Jarmulowicz M; Cassoni A; Kottaridis P; Peggs K; Mackinnon S
Biol Blood Marrow Transplant; 2006 Jan; 12(1):75-83. PubMed ID: 16399571
[TBL] [Abstract][Full Text] [Related]
18. Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
Kim JH; Stein A; Tsai N; Schultheiss TE; Palmer J; Liu A; Rosenthal J; Forman SJ; Wong JY
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):75-81. PubMed ID: 24725691
[TBL] [Abstract][Full Text] [Related]
19. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
20. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study.
Neglia JP; Friedman DL; Yasui Y; Mertens AC; Hammond S; Stovall M; Donaldson SS; Meadows AT; Robison LL
J Natl Cancer Inst; 2001 Apr; 93(8):618-29. PubMed ID: 11309438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
